IL-33 expression is lower in current smokers at both transcriptomic and protein level
- Faiz, A.
- Mahbub, R.M.
- Boedijono, F.S.
- Tomassen, M.I.
- Kooistra, W.
- Timens, W.
- Nawijn, M.
- Hansbro, P.M.
- Johansen, M.D.
- Pouwels, S.D.
- Heijink, I.H.
- Massip, F.
- de Biase, M.S.
- Schwarz, R.F.
- Adcock, I.M.
- Chung, K.F.
- van der Does, A.
- Hiemstra, P.S.
- Goulaouic, H.
- Xing, H.
- Abdulai, R.
- de Rinaldis, E.
- Cunoosamy, D.
- Harel, S.
- Lederer, D.
- Nivens, M.C.
- Wark, P.A.
- Kerstjens, H.A.M.
- Hylkema, M.N.
- Brandsma, C.A.
- van den Berge, M.
DOIAbstract
INTRODUCTION: IL-33 is a pro-inflammatory cytokine thought to play a role in the pathogenesis of asthma and COPD. A recent clinical trial using the anti-IL33 antibody showed a reduction in exacerbation and improved lung function in ex-smokers but not current smokers with COPD. In this study, we aimed to understand the effects of smoking status on IL-33. METHODS: We investigated the association of smoking status with the level of gene expression of IL33 in the airways in eight independent transcriptomic studies of lung airways. Additionally, we performed western blot and immunohistochemistry for IL-33 in lung tissue to assess protein levels. RESULTS: Across the bulk RNA-sequencing datasets, IL-33 gene expression and its signaling pathway wer...
Add to ORKG